Difference between revisions of "Ticagrelor (Brilinta)"
Jump to navigation
Jump to search
m |
|||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
'''Note that this agent does not have a hematology-specific indication at this time.''' | '''Note that this agent does not have a hematology-specific indication at this time.''' | ||
| − | * | + | *2011-07-20: Initial approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction). |
| − | * | + | *2015-09-03: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). |
==Also known as== | ==Also known as== | ||
Latest revision as of 13:17, 9 May 2023
General information
Class/mechanism: Reversible cyclopentyl-triazolo-pyrimidine class inhibitor of the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.
Route: PO
Extravasation: n/a
History of changes in FDA indication
Note that this agent does not have a hematology-specific indication at this time.
- 2011-07-20: Initial approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).
- 2015-09-03: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
Also known as
- Brand names: Brilinta, Brilique, Ticalog